Annovis BioNYSE: ANVS

Annovis (ANVS) surges 76% on Jul 2 after meeting the primary and secondary goals with statistical significance in the late-stage PD study of its lead candidate, buntanetap.

Annovis Bio (NYSE: ANVS ) stock closed up a staggering 76% today on promising new data from its Phase 3 clinical study of its Parkinson's treatment, buntanetap. Early results show that its buntanetap is both safe and effective in treating patients with early Parkinson's, helping them retain and improve both motor and non-motor activities and cognitive functions.

Annovis Bio Inc.'s stock rocketed 119% on Tuesday after the biotech reported positive results in a late-stage trial of its Parkinson's disease treatment called buntanetap.

MALVERN, Pa., June 26, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer's Disease (AD) and Parkinson's Disease (PD), announces the filing of the new composition of matter patent with the U.S. Patent and Trademark Office covering novel solid forms of buntanetap, selecting the best crystal, and building upon the provisional patent filed in June 2023.

MALVERN, Pa., June 11, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage drug platform company developing novel therapies for neurodegenerative diseases such as Alzheimer's (AD) and Parkinson's disease (PD), today announces that its recent Phase II/III Alzheimer's study of its lead drug candidate, Buntanetap, showed statistically significant efficacy and safety in both carriers and non-carriers of Apolipoprotein E4 (APOE4), a genetic cause of AD.

The mean of analysts' price targets for Annovis Bio (ANVS) points to a 359.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Glancy Prongay & Murray LLP, a prominent national law firm, has started investigating Annovis Bio, Inc. for potential breaches of federal securities laws. Investors who have incurred losses or are interested in exploring legal options under these laws are encouraged to contact the firm.

The Law Offices of Frank R. Cruz is investigating Annovis Bio, Inc. for potential violations of federal securities laws related to the company's announcement about its Alzheimer's drug. Shareholders who have suffered losses can participate in the investigation. On April 29, 2024, Annovis announced positive results for its drug buntanetap in a small subgroup of patients.

On Monday, Annovis Bio announced that its Alzheimer's treatment demonstrated a notable increase in cognitive improvement among patients with the disease in a mid-stage trial.